Leukemia - Table of Contents alert Volume 32 Issue 5

If you are unable to see the message below, click here to view.

TABLE OF CONTENTS Volume 32, Issue 5 (May 2018) In this issue Editorial Review Article Article Brief Communication Correspondence Also new AOP   Advertisement Nature Outlook: Cancer immunotherapy Drugs that mobilize our immune systems against cancer are dramatically improving care for many people, and research is rapidly moving ahead in the lab and the clinic. Access this Outlook free >> Produced with support from: F. Hoffmann-La Roche Ltd   Medimmune  Produced with support of a grant from Merck & Co., Inc. Editorial Managing myeloproliferative neoplasms evidence based on the ELN treatment recommendations 2018 Florian H. Heidel, Robert Peter Gale & Andreas Hochhaus Leukemia 2018 32 :1055 - 1056; February 27, 2018; 10.1038/s41375-018-0079-z   Abstract | Full Text Review Article Philadelphia chromosome-negative classical myeloproliferative neoplasms: revised management recommendations from European LeukemiaNet Tiziano Barbui, Ayalew Tefferi, Alessandro M. Vannucchi, Francesco Passamonti, Richard T. Silver et al. Leukemia 2018 32 :1057 - 1069; February 27, 2018; 10.1038/s41375-018-0077-1   Abstract | Full Text ERIC recommendations for TP53 mutation analysis in chronic lymphocytic leukemia—update on methodological approaches and results interpretation J. Malcikova, E. Tausch, D. Rossi, L. A. Sutton, T. Soussi et al. Leukemia 2018 32 :1070 - 1080; February 02, 2018; 10.1038/s41375-017-0007-7   Abstract | Full Text We skip to work: alternative splicing in normal and malignant myelopoiesis Alex C. H. Wong, John E. J. Rasko & Justin J.-L. Wong Leukemia 2018 32 :1081 - 1093; January 30, 2018; 10.1038/s41375-018-0021-4   Abstract | Full Text Hypomethylating agents in combination with immune checkpoint inhibitors in acute myeloid leukemia and myelodysplastic syndromes Naval Daver, Prajwal Boddu, Guillermo Garcia-Manero, Shalini Singh Yadav, Padmanee Sharma et al. Leukemia 2018 32 :1094 - 1105; February 22, 2018; 10.1038/s41375-018-0070-8   Abstract | Full Text SAMD9 and SAMD9L in inherited predisposition to ataxia, pancytopenia, and myeloid malignancies Josef Davidsson, Andreas Puschmann, Ulf Tedgård, David Bryder, Lars Nilsson et al. Leukemia 2018 32 :1106 - 1115; February 25, 2018; 10.1038/s41375-018-0074-4   Abstract | Full Text Mobilization of hematopoietic stem cells as a result of innate immunity-mediated sterile inflammation in the bone marrow microenvironment—the involvement of extracellular nucleotides and purinergic signaling Mariusz Z Ratajczak, Mateusz Adamiak, Monika Plonka, Ahmed Abdel-Latif & Janina Ratajczak Leukemia 2018 32 :1116 - 1123; March 05, 2018; 10.1038/s41375-018-0087-z   Abstract | Full Text Article Epigenetic heterogeneity affects the risk of relapse in children with t(8;21)RUNX1-RUNX1T1-rearranged AML Matteo Zampini, Claudia Tregnago, Valeria Bisio, Luca Simula, Giulia Borella et al. Leukemia 2018 32 :1124 - 1134; February 02, 2018; 10.1038/s41375-017-0003-y   Abstract | Full Text Pharmacologic inhibition of STAT5 in acute myeloid leukemia Bettina Wingelhofer, Barbara Maurer, Elizabeth C. Heyes, Abbarna A. Cumaraswamy, Angelika Berger-Becvar et al. Leukemia 2018 32 :1135 - 1146; February 02, 2018; 10.1038/s41375-017-0005-9   Abstract | Full Text Oncogenic activation of JAK3-STAT signaling confers clinical sensitivity to PRN371, a novel selective and potent JAK3 inhibitor, in natural killer/T-cell lymphoma M. -L. Nairismägi, M. E. Gerritsen, Z. M. Li, G. C. Wijaya, B. K. H. Chia et al. Leukemia 2018 32 :1147 - 1156; February 02, 2018; 10.1038/s41375-017-0004-x   Abstract | Full Text PI3K orchestration of the in vivo persistence of chimeric antigen receptor-modified T cells Wenting Zheng, Carol E. O’Hear, Rajshekhar Alli, Jacob H. Basham, Hossam A. Abdelsamed et al. Leukemia 2018 32 :1157 - 1167; February 02, 2018; 10.1038/s41375-017-0008-6   Abstract | Full Text CAR T-cells targeting FLT3 have potent activity against FLT3−ITD+ AML and act synergistically with the FLT3-inhibitor crenolanib Hardikkumar Jetani, Irene Garcia-Cadenas, Thomas Nerreter, Simone Thomas, Julian Rydzek et al. Leukemia 2018 32 :1168 - 1179; February 05, 2018; 10.1038/s41375-018-0009-0   Abstract | Full Text miR-34c-5p promotes eradication of acute myeloid leukemia stem cells by inducing senescence through selective RAB27B targeting to inhibit exosome shedding Danyue Peng, Huifang Wang, Lei Li, Xiao Ma, Ying Chen et al. Leukemia 2018 32 :1180 - 1188; February 02, 2018; 10.1038/s41375-018-0015-2   Abstract | Full Text Revised cytogenetic risk stratification in primary myelofibrosis: analysis based on 1002 informative patients Ayalew Tefferi, Maura Nicolosi, Mythri Mudireddy, Terra L. Lasho, Naseema Gangat et al. Leukemia 2018 32 :1189 - 1199; February 02, 2018; 10.1038/s41375-018-0018-z   Abstract | Full Text Blast phase myeloproliferative neoplasm: Mayo-AGIMM study of 410 patients from two separate cohorts Ayalew Tefferi, Mythri Mudireddy, Francesco Mannelli, Kebede H. Begna, Mrinal M. Patnaik et al. Leukemia 2018 32 :1200 - 1210; February 02, 2018; 10.1038/s41375-018-0019-y   Abstract | Full Text The cell fate determinant Scribble is required for maintenance of hematopoietic stem cell function Juliane Mohr, Banaja P. Dash, Tina M. Schnoeder, Denise Wolleschak, Carolin Herzog et al. Leukemia 2018 32 :1211 - 1221; January 30, 2018; 10.1038/s41375-018-0025-0   Abstract | Full Text Defining therapy goals for major molecular remission in chronic myeloid leukemia: results of the randomized CML Study IV Susanne Saussele, Rüdiger Hehlmann, Alice Fabarius, Sabine Jeromin, Ulrike Proetel et al. Leukemia 2018 32 :1222 - 1228; February 26, 2018; 10.1038/s41375-018-0055-7   Abstract | Full Text Brief Communication Detection of recurrent and of novel fusion transcripts in myeloid malignancies by targeted RNA sequencing Anna Stengel, Niroshan Nadarajah, Torsten Haferlach, Frank Dicker, Wolfgang Kern et al. Leukemia 2018 32 :1229 - 1238; February 26, 2018; 10.1038/s41375-017-0002-z   Abstract | Full Text Simultaneous multiple interaction T-cell engaging (SMITE) bispecific antibodies overcome bispecific T-cell engager (BiTE) resistance via CD28 co-stimulation Colin E. Correnti, George S. Laszlo, Willem J. de van der Schueren, Colin D. Godwin, Ashok Bandaranayake et al. Leukemia 2018 32 :1239 - 1243; January 31, 2018; 10.1038/s41375-018-0014-3   Abstract | Full Text The importance of bone marrow examination in patients with light chain amyloidosis achieving a complete response Surbhi Sidana, Nidhi Tandon, Angela Dispenzieri, Morie A. Gertz, S. Vincent Rajkumar et al. Leukemia 2018 32 :1243 - 1246; January 30, 2018; 10.1038/s41375-018-0022-3   Abstract | Full Text Selective inhibition of leukemia-associated SHP2E69K mutant by the allosteric SHP2 inhibitor SHP099 X Sun, Y Ren, S Gunawan, P Teng, Z Chen et al. Leukemia 2018 32 :1246 - 1249; January 30, 2018; 10.1038/s41375-018-0020-5   Abstract | Full Text IDH1R132, IDH2R140 and IDH2R172 in AML: different genetic landscapes correlate with outcome and may influence targeted treatment strategies Manja Meggendorfer, Luca Vincenzo Cappelli, Wencke Walter, Claudia Haferlach, Wolfgang Kern et al. Leukemia 2018 32 :1249 - 1253; January 30, 2018; 10.1038/s41375-018-0026-z   Abstract | Full Text Sex and degree of severity influence the prognostic impact of anemia in primary myelofibrosis: analysis based on 1109 consecutive patients Maura Nicolosi, Mythri Mudireddy, Terra L. Lasho, Curtis A. Hanson, Rhett P. Ketterling et al. Leukemia 2018 32 :1254 - 1258; January 30, 2018; 10.1038/s41375-018-0028-x   Abstract | Full Text Genomic profiling reveals spatial intra-tumor heterogeneity in follicular lymphoma Shamzah Araf, Jun Wang, Koorosh Korfi, Celine Pangault, Eleni Kotsiou et al. Leukemia 2018 32 :1258 - 1263; February 08, 2018; 10.1038/s41375-018-0043-y   Abstract | Full Text Correspondence (In)convenience of adding age and comorbidities to prognostic models in myelodysplastic syndromes Xavier Calvo, Lourdes Florensa & Leonor Arenillas Leukemia 2018 32 :1264 - 1266; February 22, 2018; 10.1038/s41375-018-0064-6   Abstract | Full Text Advertisement Nature Briefing is an essential round-up of science news, opinion and analysis, free in your inbox every weekday. With Nature Briefing, we'll keep you updated on the latest research, so you can focus on yours. Click here to sign up. Natureevents is a fully searchable, multi-disciplinary database designed to maximise exposure for events organisers. The contents of the Natureevents Directory are now live. The digital version is available here. Find the latest scientific conferences, courses, meetings and symposia on natureevents.com. For event advertising opportunities across the Nature Publishing Group portfolio please contact natureevents@nature.com More Nature Events Please note that you need to be a subscriber or site-licence holder to enjoy full-text access to Leukemia. In order to do so, please purchase a subscription. You have been sent this Table of Contents Alert because you have opted in to receive it. You can change or discontinue your e-mail alerts at any time, by modifying your preferences on your nature.com account at: www.nature.com/nams/svc/myaccount (You will need to log in to be recognised as a nature.com registrant). For further technical assistance, please contact our registration department. For print subscription enquiries, please contact our subscription department. For other enquiries, please contact our customer feedback department. Springer Nature |One New York Plaza, Suite 4500 | New York | NY 10004-1562 | USA Springer Nature's worldwide offices: London - Paris - Munich - New Delhi - Tokyo - Melbourne San Diego - San Francisco - Washington - New York - Boston Macmillan Publishers Limited is a company incorporated in England and Wales under company number 785998 and whose registered office is located at The Campus, 4 Crinan Street, London, N1 9XW. © 2018 Macmillan Publishers Limited, part of Springer Nature. All Rights Reserved.